Novacyt S.A. (CDI) (NCYT)

Sector:

Health Care

Index:

FTSE AIM All-Share

189.00p
   
  • Change Today:
    -49.90p
  • 52 Week High: 1,190.00
  • 52 Week Low: 188.93
  • Currency: UK Pounds
  • Shares Issued: 70.63m
  • Volume: 1,652,082
  • Market Cap: £133.48m
  • RiskGrade: 453

NCYT Overview

The Novacyt Group is a rapidly growing, international diagnostics group with a growing portfolio of cancer and infectious disease products and services. Through its proprietary technology platform, NOVAPrep®, and molecular platform, genesig®, Novacyt is able to provide an extensive range of oncology and infectious disease diagnostic products across an extensive international distributor network. The Group has diversified sales from diagnostic reagents used in oncology, microbiology, haematology and serology markets, and its global customers and partners include major corporates.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn 60.4% n/a
ROCE 126.9%  
Latest F'cast
P/E 1.2 n/a
PEG n/a n/a
Pr/Revenue 0.6 n/a
Pr/Book 1.1  
Latest F'cast
Revenue 2316.7% n/a
PBT n/a n/a
EPS n/a -100.0%
DPS n/a n/a

NCYT Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-16 11.08 (5.71) (47.00)¢ n/a n/a n/a n/a 0.0%
31-Dec-17 12.75 (3.49) (15.00)¢ n/a n/a n/a n/a 0.0%
31-Dec-18 13.72 (2.08) (6.00)¢ n/a n/a n/a n/a 0.0%
31-Dec-19 11.47 (3.43) (8.00)p n/a n/a n/a n/a 0.0%
31-Dec-20 277.20 165.17 194.00p 4.4 n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

NCYT Forecasts

Year Ending Revenue ( m) Pre-tax ( m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-21 n/a n/a n/a n/a n/a -100% n/a 0.0%
31-Dec-22 n/a n/a n/a n/a n/a n/a n/a 0.0%
31-Dec-23 n/a n/a n/a n/a n/a n/a n/a 0.0%

Copyright © 2022 FactSet Research Systems Inc. All rights reserved.

Latest NCYT Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

NCYT Market Data

Currency UK Pounds
Share Price 189.00p
Change Today -49.90p
% Change -20.89 %
52 Week High 1,190.00
52 Week Low 188.93
Volume 1,652,082
Shares Issued 70.63m
Market Cap £133.48m
RiskGrade 453

NCYT Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
79.41% above the market average79.41% above the market average79.41% above the market average79.41% above the market average79.41% above the market average
83.33% above the sector average83.33% above the sector average83.33% above the sector average83.33% above the sector average83.33% above the sector average
Price Trend
40.01% below the market average40.01% below the market average40.01% below the market average40.01% below the market average40.01% below the market average
7.32% below the sector average7.32% below the sector average7.32% below the sector average7.32% below the sector average7.32% below the sector average
Income Not Available
Growth
67.54% above the market average67.54% above the market average67.54% above the market average67.54% above the market average67.54% above the market average
82.35% above the sector average82.35% above the sector average82.35% above the sector average82.35% above the sector average82.35% above the sector average

NCYT Dividends

No dividends found

Trades for 25-Jan-2022

Time Volume / Share Price
12:55 2,000 @ 194.01p
12:54 500 @ 194.79p
12:51 515 @ 192.76p
12:50 263 @ 189.00p
12:50 178 @ 190.00p

NCYT Key Personnel

CFO James McCarthy
CEO David Allmond

Top of Page